AccScience Publishing / ARNM / Volume 1 / Issue 2 / DOI: 10.36922/arnm.0963
Cite this article
Journal Browser
Volume | Year
News and Announcements
View All

Evaluating the efficacy of immunochemoradiotherapy in malignant pleural mesothelioma and distinguishing benign from malignant lymph nodes using 18F-FDG PET/CT and 18F-FAPI-04 PET/CT imaging: A case report

Mengye Peng1 Menglu Wang1 Ying Zhang1 Tingting Wu1 Kezheng Wang1*
Show Less
1 Department of PET-CT, Harbin Medical University Cancer Hospital, Harbin, China
Submitted: 19 May 2023 | Accepted: 4 September 2023 | Published: 7 November 2023
© 2023 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( )

In this paper, we report a case of pleural mesothelioma, imaged employing 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT), and 18F-fibroblast activating protein inhibitor (FAPI)-04 PET/CT. The diagnosis of pleural mesothelioma was confirmed by histopathologically examining the thoracoscopic biopsy. The patient underwent an 18F-FDG PET/CT before immunochemoradiotherapy, followed by an 18F-FAPI-04 imaging 3 months after treatment. The changes in focal anatomy, morphology, and metabolic biology observed between the two distinct PET/CT imaging modalities can aid in distinguishing benign and malignant lymph nodes and assessing treatment efficacy. This case highlights the diagnostic utility of 18F-FDG PET/C in pleural mesothelioma and suggests that 18F-FAPI-04 PET/CT may serve as an effective tool for evaluating the outcomes of immunochemotherapy. Moreover, the combined application of 18F-FDG PET/CT and 18F-FAPI-04 PET/CT holds promise for the differentiation of benign and malignant lymph nodes.

Fibroblast activation protein inhibitor
Malignant mesothelioma
Positron emission tomography/computed tomography
National Natural Science Foundation of China General Projects
Provincial Key Research and Development Program of Heilongjiang Province
Postdoctoral Special Scientific Research Grant of Heilongjiang Provincial Government
Distinguished Young Scientist Funding of Harbin Medical University Affiliated Tumor Hospital
Key Project of the Climbing Funding of the National Cancer Center
  1. Hathi DK, Jones EF, 2019, 68Ga FAPI PET/CT: Tracer uptake in 28 different kinds of cancer. Radiol Imaging Cancer, 1: e194003.


  1. Mona CE, Benz MR, Hikmat F, et al., 2022, Correlation of 68Ga-FAPi-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: Interim analysis of a prospective translational exploratory study. J Nucl Med, 63: 1021–1026.


  1. Giesel FL, Kratochwil C, Schlittenhardt J, et al., 2021, Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients. Eur J Nucl Med Mol Imaging, 48: 4377–4385.
  2. Gundogan C, Guzel Y, Komek H, et al., 2022, 68Ga-FAPI-04 PET/CT versus 18F-FDG PET/CT in malignant peritoneal mesothelioma. Clin Nucl Med, 47: e113–e115.


  1. Kessler L, Ferdinandus J, Hirmas N, et al., 2022, 68Ga-FAPI as a diagnostic tool in sarcoma: Data from the 68Ga-FAPI PET prospective observational trial. J Nucl Med, 63: 89–95.


  1. Treglia G, Muoio B, Roustaei H, et al., 2021, Head-to-head comparison of fibroblast activation protein inhibitors (FAPI) radiotracers versus [18F]F-FDG in oncology: A systematic review. Int J Mol Sci, 22: 11192.


  1. Armato SG 3rd, Labby ZE, Coolen J, et al., 2013, Imaging in pleural mesothelioma: A review of the 11th International Conference of the International Mesothelioma Interest Group. Lung Cancer, 82: 190–196.


  1. Armato SG 3rd, Ogarek JL, Starkey A, et al., 2006, Variability in mesothelioma tumor response classification. AJR Am J Roentgenol, 186: 1000–1006.


  1. Oxnard GR, Armato SG 3rd, Kindler HL, 2006, Modeling of mesothelioma growth demonstrates weaknesses of current response criteria. Lung Cancer, 52: 141–148.


  1. Ceresoli GL, Chiti A, Zucali PA, et al., 2007, Assessment of tumor response in malignant pleural mesothelioma. Cancer Treat Rev, 33: 533–541.


  1. Lopci E, Zucali PA, Ceresoli GL, et al., 2015, Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma. Eur J Nucl Med Mol Imaging, 42: 667–675.


  1. Spitilli MG, Treglia G, Calcagni ML, et al., 2007, Malignant pleural mesothelioma: Utility of 18 F-FDG PET. Ann Ital Chir, 78: 393–396.


  1. Sandach P, Seifert R, Fendler WP, et al., 2022, A role for PET/CT in response assessment of malignant pleural mesothelioma. Semin Nucl Med, 52: 816–823.


  1. Kitajima K, Doi H, Kuribayashi K, 2016, Present and future roles of FDG-PET/CT imaging in the management of malignant pleural mesothelioma. Jpn J Radiol, 34: 537–547.


  1. Dong A, Zhao B, Cheng C, et al., 2022, 68 Ga-FAPI-04 versus 18 F-FDG PET/CT in detection of epithelioid malignant pleural mesothelioma. Clin Nucl Med, 47: 980–981.


  1. Li J, Yang J, Hu S, 2023, Malignant peritoneal mesothelioma with butterfly-shaped muscle metastasis: 68Ga-FAPI PET/ CT versus 18F-FDG PET/CT. Clin Nucl Med, 48: 348–350.


  1. Guzel Y, Komek H, Can C, et al., 2023, Comparison of the role of 18 F-fluorodeoxyglucose PET/computed tomography and 68 Ga-labeled FAP inhibitor-04 PET/CT in patients with malignant mesothelioma. Nucl Med Commun, 44: 631–639.


  1. Hu K, Wang L, Wu H, et al., 2022, [18F]FAPI-42 PET imaging in cancer patients: Optimal acquisition time, biodistribution, and comparison with [68Ga]Ga-FAPI-04. Eur J Nucl Med Mol Imaging, 49: 2833–2843.


  1. Shu Q, Deng M, Hu M, et al., 2023, The additional role of [68Ga]Ga-FAPI-04 PET/CT in patients with unknown primary lesion with a negative or equivocal [18F]FDG. Eur J Nucl Med Mol Imaging, 50: 1442–1452.
Conflict of interest
The authors report no conflict of interest in this paper.
Back to top
Advances in Radiotherapy & Nuclear Medicine, Electronic ISSN: 2972-4392 Published by AccScience Publishing